Sign In
Buy NUVL
$90.18
-1.17 (-1.28%)
At Close: Jun 03, 2026
Achievement of all anticipated 2024 milestones and accelerated development timelines reinforce progress on OnTarget 2026 operating plan towards first approved product in 2026 Leading medical oncologis
Nuvalent: Promising Data Keeps Validating Pipeline And Platform
12:34pm, Monday, 23'rd Sep 2024
Nuvalent's lead candidates, NVL-520 and NVL-655, show promising efficacy and safety in Phase 1/2 trials. Both drugs have received FDA Breakthrough Therapy and orphan drug designations, with pivotal Ph
Nuvalent Announces Closing of Upsized Public Offering of Common Stock
04:05pm, Wednesday, 18'th Sep 2024
CAMBRIDGE, Mass. , Sept. 18, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kin
Nuvalent Stock Moves Up 20% in a Week: What's Driving the Rally?
03:31pm, Wednesday, 18'th Sep 2024
The upside comes after NUVL reported encouraging data on two experimental lung cancer therapies.
Nuvalent: NSCLC Program Now Lends Credibility Towards 2025 Pivotal Data Releases
01:20pm, Tuesday, 17'th Sep 2024
Nuvalent, Inc. achieved positive data from the phase 1/2 ALKOVE-1 study, using NVL-655 for the treatment of patients with ALK-mutant NSCLC. Positive data achieved from phase 1/2 ARROS-1 study, using z
Nuvalent Announces Pricing of Upsized Public Offering of Common Stock
10:23pm, Monday, 16'th Sep 2024
CAMBRIDGE, Mass. , Sept. 16, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kin
Nuvalent Stock Jumps On ESMO Data Presentation, Seeks To Raise $350M Via Equity
01:44pm, Monday, 16'th Sep 2024
Over the weekend, Nuvalent, Inc. NUVL highlighted the presentation of updated data from Phase 1 dose-escalation portions of the ongoing ARROS-1 Phase 1/2 trial of zidesamtinib and ALKOVE-1 Phase 1/2
Nuvalent Flies On 'Multibillion-Dollar' Potential, While Iteos Crashes On Patient Deaths
01:05pm, Monday, 16'th Sep 2024
Biotech stocks Nuvalent and Iteos diverged Monday on updates for their lung cancer treatments at the ESMO meeting in Madrid.
Cancer Biotech Nuvalent's Stock Jumps on Positive Data
11:18am, Monday, 16'th Sep 2024
Biotech Nuvalent unveiled updates on two experimental cancer medicines over the weekend. Analysts say each could be the best in their category.
Nuvalent Announces Public Offering of Common Stock
07:00am, Monday, 16'th Sep 2024
CAMBRIDGE, Mass. , Sept. 16, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kin
Updated Phase 1 dose-escalation data from ARROS-1 and ALKOVE-1 clinical trials continue to support potential best-in-class profiles for zidesamtinib and NVL-655 Rapid enrollment in Phase 2 portions of
Nuvalent Announces Publication in Cancer Discovery Detailing Design and Characterization of ALK-selective inhibitor NVL-655
09:53am, Friday, 13'th Sep 2024
Publication provides comprehensive assessment of NVL-655's preclinical activity and includes preliminary clinical case studies CAMBRIDGE, Mass. , Sept. 13, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq:
Updated Phase 1 data from ALKOVE-1 and ARROS-1 clinical trials to be presented at the ESMO Congress 2024 Durable activity of NVL-655 and zidesamtinib in heavily pre-treated patient populations support
Nuvalent to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
06:30am, Thursday, 29'th Aug 2024
CAMBRIDGE, Mass. , Aug. 29, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven ki
Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2024 Financial Results
06:30am, Thursday, 08'th Aug 2024
Company plans to host a conference call in conjunction with oral presentations at ESMO on September 14, 2024, at 8:30 a.m. ET/2:30 p.m.
